Charles Thompson, MD
Interventional Cardiology · Zachary, LANPI 1528260072
Payments from drug & device makers
Across 538 payments — averaging $243.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$61K
- Bayer$27K
- Siemens Medical Solutions USA, Inc.$17K
- AstraZeneca$8K
- Novartis$7K
- Philips North America LLC$2K
- plus $10K from 42 others
What the payments were for
- Consulting fees$7501%
- Travel & lodging$9111%
- Food & beverage$12,53917%
- Education$600%
- Other$59,25081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$60,230
- CVX-300$750
- Lasers$570
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$516
- FLOWTRIEVER CATHETER, S$301
- CT THROMBECTOMY SYSTEM KIT$301
- Impella$268
- ELUVIA$150
- General - Balloon Catheters$142
- TherOx DS2 Console$119
- Catheter$119
- Downstream Cartridge$119
- Sublime 014 Rx PTA Balloon Dilatation Catheter$116
- Sublime Microcatheter, 018, 200cm, Straight$116
- Sublime Microcatheter, 035, 200cm, Angle$116
- Sublime Radial Access Guide Sheath$116
- Indigo System$110
- AVEIR$107
- Trilogy 100$107
How this compares
$130,976 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 739 | $625,208 |
| XareltoRivaroxaban | 301 | $251,280 |
| EntrestoSacubitril/Valsartan | 179 | $180,919 |
| FarxigaDapagliflozin Propanediol | 166 | $120,153 |
| Repatha SureclickEvolocumab | 115 | $105,759 |
| BrilintaTicagrelor | 49 | $27,107 |
| JardianceEmpagliflozin | 21 | $24,383 |
| CorlanorIvabradine Hcl | 16 | $16,770 |
| NexlizetBempedoic Acid/Ezetimibe | 34 | $15,490 |
| Ranolazine ErRanolazine | 196 | $13,759 |
| Atorvastatin Calcium | 1,503 | $13,436 |
| Nifedipine ErNifedipine | 385 | $7,815 |
| Potassium Chloride | 593 | $7,792 |
| Rosuvastatin Calcium | 589 | $7,681 |
| Metoprolol Tartrate | 1,381 | $7,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $372 | $625,208739 claims |
| Johnson & JohnsonXarelto | $580 | $251,280301 claims |
| NovartisEntresto | $6,950 | $180,919179 claims |
| AstraZenecaFarxiga, Brilinta | $7,756 | $147,260215 claims |
| Boehringer IngelheimJardiance | $88 | $24,38321 claims |
| AmgenCorlanor | $385 | $16,77016 claims |
| Esperion Therapeutics, Inc.Nexlizet | $125 | $15,49034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Zachary
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
- Stephen RameeNew Orleans$1.5M
- Denzil MoraesBaton Rouge$1.4M
- James JenkinsNew Orleans$1.2M
- Ankur LodhaLafayette$945K
- Rajan PatelNew Orleans$633K
- Bruce EnnisMandeville$562K
- Jorge CastellanosBaton Rouge$561K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.